我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

血小板糖蛋白(GP)Ⅱb/Ⅲa受体拮抗剂及在冠心病临床应用的研究进展(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2000年第4期
页码:
306-308
栏目:
综述
出版日期:
2000-08-01

文章信息/Info

Title:
-
作者:
田建伟;  刘朝中;  江一清
空军总医院心内科, 北京100036
Author(s):
-
关键词:
GPⅡb/Ⅲa受体拮抗剂; PTCA术; 心绞痛; 不稳定型; 心肌梗死; 急性
Keywords:
-
分类号:
Q513.2 R543.3
DOI:
-
文献标识码:
A
摘要:
血小板在动脉粥样硬化、血栓形成以及急性冠脉综合征中起着非常重要的作用。血小板糖蛋白GPⅡb/Ⅲa受体拮抗剂通过与血小板膜上的GPⅡb/Ⅲa受体结合抑制血小板凝集,是一种新型高效的血小板抑制剂。目前已广泛地应用于冠心病、不稳定性心绞痛、急性心肌梗死(AMI)及冠心病介入治疗后并发症的防治。大系列的临床研究已取得了降低并发症及病死率的显著疗效。
Abstract:
-

参考文献/References

[1] 　Ferguson JJ,Waly HM,Wilson JM. Fundamentals of coagulation and glycoprotein Ⅱb/Ⅲa receptor inhibition［J］. Eur Heart J,1998，19(Suppl D):D3.

［2］　Isenberg WN,McEver RP,Phillips DR,et al. The platelet fibrinogen receptor:an immunogold-surface replica study of agonist-induced ligand binding and receptor clustering［J］. J Cell Biol,1987，104:1655.

［3］　Niiya K,Hodson E,Bader R,et al. Increased surface of expression of the membrane glycoprotein Ⅱb-Ⅲa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation［J］. Blood,1987，70:475.

［4］　Phillips DR,Charo IF,Scarborough RM. GPⅡb/Ⅲa: The responsive integrin［J］. Cell,1991，65:359.

［5］The EPIC investigators. Use of a monoclonal antibody directed against the glycoprotein Ⅱb/Ⅲa receptor in high-risk coronary angioplasty［J］. N Engl J Med,1994，330:956.

［6］The EPILOG investigators. Platelet glycoprotein Ⅱb/Ⅲa receptor blockade and low-dose heparin during percutaneous coronary revascularization［J］. N Engl J Med,1997，336:1689.

［7］The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina:the CAPTURE study［J］. Lancet,1997，349:1429.

［8］The IMPACT-Ⅱ investigators. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention:IMPACT-Ⅱ［J］. Lancet,1997，349:1422.

［9］The RESTORE investigators. Effects of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty［J］. Circulation,1997，96:1445.

［10］Topol EJ,Fergson JJ,Weisman HF,et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blocka de with percutaneous coronary intervention［J］. JAMA,1997，278:479.

［11］Califf RM. PURSUIT. Presented at the 70th Scientific Sessions of the American Heart Association［C］. November 9-12,1997,Orlando,Fla

［12］Van de Werf F. PARAGON. Presented at the 19th Congress of the European Society of Cardiology［C］. August 24-28,1997,Stockholm,Sweden

［13］The PRISM investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina［J］. N Engl J Med,1998，338:1498.

［14］The PRISM-PLUS investigators. Inhibition of the platelet glycoprotein Ⅱb/Ⅲa receptor with unstable angina and non-Q myocardial infarction［J］. N Engl J Med,1998，338:1488.

［15］Harrington RA. PARADIGM. Presented at the 69th Scientific Sessions of the American Heart Association［C］. November 10-13,1996,New Orleans,La

［16］Kereiakes DJ,lincoff AM,Miller DP,et al. Abciximab reduce risk of unplanned coronary stent deployment:EPILOG trial results.(Abstract)［J］. Circulation,1997;96(suppl Ⅰ):Ⅰ-163.

［17］Topol EJ,Ferguson JJ,Wersman HF,et al. Long-term protection from myocardial ischemic events in randomized trial of brief intergrin β3 blockade with percutaneous coronary intervention［J］. JAMA,1997，278:479.

备注/Memo

备注/Memo:
收稿日期：1999-06-08.
更新日期/Last Update: 2000-08-01